

# David G Maloney

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6452290/david-g-maloney-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77  
papers

8,608  
citations

35  
h-index

80  
g-index

80  
ext. papers

10,961  
ext. citations

5.4  
avg, IF

5.66  
L-index

#	Paper	IF	Citations
77	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 2123-38	15.9	1143
76	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1404-1419	24.4	649
75	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 355ra116	17.5	613
74	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. <i>Blood</i> , <b>2017</b> , 130, 2295-2306	2.2	522
73	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , <b>2003</b> , 102, 756-62	2.2	488
72	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> , <b>2016</b> , 127, 2406-10	2.2	436
71	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3010-3020	2.2	396
70	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet, The</i> , <b>2020</b> , 396, 839-852	40	387
69	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , <b>2003</b> , 102, 3447-54	2.2	346
68	Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4246-54	2.2	320
67	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>1997</b> , 90, 4705-4709	2.2	288
66	Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3249-56	2.2	273
65	Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , <b>2007</b> , 110, 4606-13	2.2	262
64	Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4912-20	2.2	228
63	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood</i> , <b>2018</b> , 131, 121-130	2.2	225
62	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1195-203	21.7	225
61	Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1530-8	2.2	164

60	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , <b>2019</b> , 133, 1652-1663	2.2	158
59	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , <b>2019</b> , 133, 1876-1887	2.2	126
58	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , <b>2020</b> , 135, 1650-1660	2.2	115
57	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 26-33	4.7	100
56	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , <b>2019</b> , 134, 636-640	2.2	89
55	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit SALLS <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 218	19.4	75
54	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , <b>2014</b> , 124, 287-95	2.2	66
53	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 1011-1011	2.2	62
52	Nonmyeloablative Hematopoietic Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 938, 328-339	6.5	55
51	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , <b>2019</b> , 6, e409-e418	14.6	53
50	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. <i>Cancer Cell</i> , <b>2021</b> , 39, 193-208.e10	24.3	50
49	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 697-703	2.2	50
48	Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1363-8	4.7	47
47	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. <i>Expert Review of Hematology</i> , <b>2019</b> , 12, 195-205	2.8	44
46	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 34-43	4.7	40
45	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , <b>2021</b> , 137, 323-335	2.2	39
44	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , <b>2019</b> , 3, 3062-3069	7.8	37
43	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , <b>2015</b> , 126, 184-184	2.2	36

42	Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 105-12	4.7	34
41	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <i>Haematologica</i> , <b>2014</b> , 99, 1624-31	6.6	32
40	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 574-83	4.5	29
39	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3773-3773	2.2	29
38	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , <b>2019</b> , 3, 3590-3601	7.8	27
37	Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 792-8	4.7	22
36	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , <b>2019</b> , 104, 380-391	6.6	19
35	Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age $\geq 60$ years with B cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 770-5	4.7	18
34	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , <b>2021</b> ,	21.7	18
33	Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 281-7	4.7	16
32	Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 509-19	12.5	16
31	Diversity in antibody-based approaches to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51 Suppl 1, 20-7	1.9	14
30	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1582-1587	4.7	12
29	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. <i>Blood Advances</i> , <b>2017</b> , 1, 2247-2256	7.8	11
28	Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. <i>Hematological Oncology</i> , <b>2015</b> , 33, 187-91	1.3	10
27	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2383-2387	4.7	10
26	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 56-56	2.2	10
25	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , <b>2020</b> , 4, 4869-4872	7.8	8

24	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>1997</b> , 90, 4705-4709	2.2	7
23	Long-Term Follow-Up of Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2211-2215	4.7	6
22	A phase I/II trial of iodine-131Bositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , <b>2000</b> , 96, 2934-2942	2.2	6
21	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. <i>Blood Advances</i> , <b>2021</b> ,	7.8	5
20	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2020</b> , 34, 957-970	3.1	5
19	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 57.e1-57.e8		5
18	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	4
17	A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥0 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.. <i>Blood</i> , <b>2005</b> , 106, 487-487	2.2	4
16	Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 140	22.4	4
15	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Rituximab. <i>Blood</i> , <b>2019</b> , 133, 1161-1161	2.2	3
14	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20 B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1811-1818	4.7	3
13	Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	3
12	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy <b>2021</b> ,		3
11	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 390-395	2	2
10	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 38-39	2.2	2
9	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study <b>2021</b> , 9,		1
8	Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond. <i>Hematology/Oncology Clinics of North America</i> , <b>2021</b> , 35, 847-862	3.1	0
7	Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen.. <i>Blood</i> , <b>2007</b> , 110, 1905-1905	2.2	

- 6 Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma. *Blood*, **2014**, 124, 3967-3967 2.2
- 5 A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2012**, 120, 1924-1924 2.2
- 4 Effect of Rituximab On the Activity of T Cells Expressing CD20-Specific Chimeric Antigen Receptors. *Blood*, **2012**, 120, 4222-4222 2.2
- 3 Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. *Blood*, **2012**, 120, 354-354 2.2
- 2 Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. *Transplantation and Cellular Therapy*, **2021**, 27, 163.e1-163.e7
- 1 Indolent lymphomas: current and emerging treatment approaches. *Clinical Advances in Hematology and Oncology*, **2006**, 4, 1-10; quiz 11-2 0.6